Physician profile
John P Mcdermott
NPI 1386663854
$14,485.12
in general payments reported to CMS, 2019-2025
44 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $1,454 · 2021: $2,095 · 2022: $2,293 · 2023: $2,197 · 2024: $2,405 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,364.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,343.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,750.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,674.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,403.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $827.79 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $776.02 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $731.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $576.11 | 2019-2025 | Belsomra, Gardasil 9, Steglatro |
| Teva Pharmaceuticals USA, INC. | $525.51 | 2019-2024 | Austedo Xr, Ajovy |
| Abbvie INC. | $490.44 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $403.96 | 2019-2022 | |
| Amarin Pharma, INC. | $372.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $358.73 | 2022-2025 | |
| Abbott Laboratories | $253.73 | 2022-2025 | Freestyle Libre |
| Amgen INC. | $208.31 | 2019-2025 | Evenity, Repatha, Otezla |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.